PT3133923T - Terapêutica génica baseada em aav para esclerose múltipla - Google Patents

Terapêutica génica baseada em aav para esclerose múltipla

Info

Publication number
PT3133923T
PT3133923T PT157823329T PT15782332T PT3133923T PT 3133923 T PT3133923 T PT 3133923T PT 157823329 T PT157823329 T PT 157823329T PT 15782332 T PT15782332 T PT 15782332T PT 3133923 T PT3133923 T PT 3133923T
Authority
PT
Portugal
Prior art keywords
aav
gene therapy
multiple sclerosis
based gene
sclerosis
Prior art date
Application number
PT157823329T
Other languages
English (en)
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of PT3133923T publication Critical patent/PT3133923T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PT157823329T 2014-04-24 2015-04-24 Terapêutica génica baseada em aav para esclerose múltipla PT3133923T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983924P 2014-04-24 2014-04-24

Publications (1)

Publication Number Publication Date
PT3133923T true PT3133923T (pt) 2020-09-04

Family

ID=54333299

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157823329T PT3133923T (pt) 2014-04-24 2015-04-24 Terapêutica génica baseada em aav para esclerose múltipla

Country Status (15)

Country Link
US (3) US20170043036A1 (pt)
EP (2) EP3133923B1 (pt)
JP (3) JP6646282B2 (pt)
AU (2) AU2015249328B2 (pt)
CA (1) CA2945984C (pt)
CY (1) CY1123312T1 (pt)
DK (1) DK3133923T3 (pt)
ES (1) ES2814280T3 (pt)
HR (1) HRP20201342T1 (pt)
HU (1) HUE050681T2 (pt)
LT (1) LT3133923T (pt)
PT (1) PT3133923T (pt)
RS (1) RS60816B1 (pt)
SI (1) SI3133923T1 (pt)
WO (1) WO2015164789A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7270946B2 (ja) * 2017-08-08 2023-05-11 国立大学法人浜松医科大学 自己免疫疾患の治療又は予防剤
CN114555063A (zh) * 2019-06-04 2022-05-27 托马斯杰斐逊大学 用于治疗多发性硬化症的少突胶质细胞来源的细胞外囊泡
EP4135852A1 (en) * 2020-04-14 2023-02-22 University Of Florida Research Foundation, Incorporated Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis
WO2021211614A1 (en) * 2020-04-14 2021-10-21 University Of Florida Research Foundation, Incorporated Aav-based gene therapies for treatment of autoimmune diseases
WO2024081570A1 (en) * 2022-10-10 2024-04-18 Eli Lilly And Company Methods and systems for using causal networks to develop models for evaluating biological processes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen
AU5588298A (en) * 1996-12-02 1998-06-29 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
KR100449454B1 (ko) * 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
ATE270306T1 (de) * 2000-10-02 2004-07-15 Univ Yonsei Seoul Einkettige insulinanaloge
CA2361462A1 (en) * 2001-11-07 2003-05-08 Katherine A. High Induction of tolerance to a therapeutic polypeptide
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
US20090304726A1 (en) * 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
DK2364362T3 (en) * 2008-11-12 2016-01-25 Ospedale San Raffaele Srl Gene vector FOR INDUCTION OF IMMUNE TOLERANCE transgene
AU2012225749B2 (en) * 2011-03-04 2015-01-22 Intrexon Corporation Vectors conditionally expressing protein
WO2013045488A1 (en) * 2011-09-26 2013-04-04 Universität Zürich Prorektorat Mnw Apc-mediated tolerance induction for therapy of multiple sclerosis
EP3071224B1 (en) * 2013-11-22 2019-01-09 Amarna Holding B.V. Method for restoring immune tolerance in vivo

Also Published As

Publication number Publication date
ES2814280T3 (es) 2021-03-26
CA2945984C (en) 2023-09-26
CY1123312T1 (el) 2021-12-31
EP3744177A1 (en) 2020-12-02
JP2017513500A (ja) 2017-06-01
CA2945984A1 (en) 2015-10-29
DK3133923T3 (da) 2020-08-10
LT3133923T (lt) 2020-08-25
US20170043036A1 (en) 2017-02-16
JP2020062038A (ja) 2020-04-23
SI3133923T1 (sl) 2020-11-30
JP7430898B2 (ja) 2024-02-14
AU2015249328A1 (en) 2016-10-27
EP3133923A1 (en) 2017-03-01
RS60816B1 (sr) 2020-10-30
US20200138978A1 (en) 2020-05-07
AU2015249328B2 (en) 2019-01-17
HUE050681T2 (hu) 2020-12-28
WO2015164789A1 (en) 2015-10-29
US20230381342A1 (en) 2023-11-30
AU2019202958B2 (en) 2021-08-05
JP2022081549A (ja) 2022-05-31
AU2019202958A1 (en) 2019-05-16
HRP20201342T1 (hr) 2020-11-27
EP3133923B1 (en) 2020-06-03
EP3133923A4 (en) 2017-12-27
JP6646282B2 (ja) 2020-02-14

Similar Documents

Publication Publication Date Title
IL251468A0 (en) aav-based gene therapy
IL284577A (en) Garden healing
ZA201604874B (en) Rna-guided gene drives
GB201420139D0 (en) Factor IX gene therapy
HUE043954T2 (hu) Szklerózis multiplex kezelése
GB201407322D0 (en) Gene therapy
LT3612237T (lt) Genų terapija
IL249254B (en) Gene expression system
PT3133923T (pt) Terapêutica génica baseada em aav para esclerose múltipla
IL257500A (en) Altered cullin1 gene
GB201707212D0 (en) Gene therapy for ciliopathies
GB201416788D0 (en) Therapeutic applications for pyocins
GB201701968D0 (en) Gene therapy
GB201513151D0 (en) Functional gene replacement therapy
GB201517329D0 (en) Diabetes gene therapy
IL263085A (en) Garden healing
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201704634D0 (en) Gene therapy
SG10201912076UA (en) Gene therapy composition
GB201410595D0 (en) Factor IX gene therapy
GB201406674D0 (en) Therapeutic